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Abstract
Structural characterization of proteins used in biological experiments is largely neglected. In most
publications, the information available is totally insufficient to judge the functionality of the proteins
used and, therefore, the significance of identified protein-protein interactions (was the interaction
specific or due to unspecific binding of misfolded protein regions?) or reliability of kinetic and
thermodynamic data (how much protein was in its native form?). As a consequence, the results of
single experiments might not only become questionable, but the whole reliability of systems
biology, built on these fundaments, would be weakened.
The introduction of Minimal Information concerning purified proteins to add as metadata to the
main body of a manuscript would render straightforward the assessment of their functional and
structural qualities and, consequently, of results obtained using these proteins. Furthermore,
accepted standards for protein annotation would simplify data comparison and exchange. This
article has been envisaged as a proposal for aggregating scientists who share the opinion that the
scientific community needs a platform for Minimum Information for Protein Functionality
Evaluation (MIPFE).
Introduction
The introduction of standards for reporting experimental
conditions and public access annotation of Minimal
Information (MI) enables the development of homogene-
ous formats for data comparison and storage, and results
in simplified data analysis and improved reproducibility.
Research and industrial labs can rationalize their work
and avoid losing information and know-how by storing
data and protocols in homogeneous formats, objectively
annotated and easily understandable. As a consequence,
the results are accessible for control, further analyses and
sharing, avoiding loss of competences once the operator
has left. Furthermore, development of software and
equipment is stimulated by having clearly defined stand-
ards. Scientific editors and funding agencies also profit
from an established repository that simplifies data access,
comparison, verification and exchange [1]. In summary,
standardization increases the global value of results, as
already described in detail [1-3]. The research communi-
ties operating in proteomics, microarray, and molecular
interactions have already progressed in organizing their
work through, for instance, the Proteomic Standard Initi-
ative [4]. The resulting guidelines were incorporated in
platforms like MIAPE, MIAME, MIMIx [3], MISFISHIE or
MIGS aimed at the complete disclosure of methodologies
used [5,6] and at description of both the data generated
and their annotation. Conformation to these standards is
already compulsory for publishing in several top journals
[7,8]. An increasing number of projects in different bio-
science fields is now organized under the umbrella of a
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central register for guidelines, the Minimal Information
for Biological and Biomedical Investigation (MIBBI, see
Availability and requirements section for URL), and
another interesting approach is represented by interactive
models as Human Proteinpedia (see Availability and
requirements section for URL) and WikiProteins [9,10].
Probably, it is time to apply analogous standardized
methods also to the field of protein, monoclonal, and
recombinant antibody production, following as a model
what has already been proposed and implemented so far
[2-4,11].
Time for MIPFE?
As mentioned in previous publications dealing with data
collection standardization, there are general reasons for
such choices, and all the parts will gain from producing
and storing "transparent" data [1,3,12,13].
A specific reason for having MI in protein production
technology is the fact that protein production is a rela-
tively accessible technique, largely performed by non-spe-
cialists. As a consequence, there is often a superficial
approach in dealing with the subject and a general under-
estimation of the critical control experiments and quality
standards. General biology journals usually do not ask for
proof that proteins used in experiments were monodis-
persed and natively folded, namely it is not possible to
evaluate the congruence of published data, since informa-
tion concerning the structure and functionality of the
experimental material is not usually reported. This situa-
tion leads to ambiguous and contradictory results, and
raises the necessity to identify a suitable and largely
accepted laboratory information management system for
protein production and characterization. The aim of this
effort would be not to emphasize demanding analyses,
but to help in finding rational and reproducible operative
conditions, by offering standardized guidelines for proce-
dures and rigorous annotations. An ideal Minimum Infor-
mation for Protein Functionality Evaluation (MIPFE)
platform to handle and characterize proteins would be
appreciated by non-specialists as well as by biochemists
and crystallographers. Furthermore, the introduction of
defined and universal protein quality standards will be
beneficial for the validation of the data used as "constitu-
tive elements" in other MI platforms, like MIMIx and
MIRIAM, which use bona fide publicly accessible results
[14].
The three basic components of such a platform should
include MI specifications, data formats, and controlled
vocabulary [2]. The Ontology for Biomedical Investiga-
tions – OBI (see Availability and requirements section for
URL) is the ongoing project aimed at providing the scien-
tific community with appropriate terminology, and
would be the reference.
Data formats are the units for information transmission,
and their choice plays a crucial role in optimizing data
sharing. The danger of fragmentation among different
platforms has been claimed [1], whilst the maximal
exploitation of research data will be possible only in a
context in which data structures are harmonized. The
Functional Genomics Experiment – FuGE (see Availability
and requirements section for URL) Project could be con-
sidered as a reference model since it was specifically cre-
ated for providing suitable Extensible Markup Language
(XML) formats for MI initiatives [15]. Future alternatives,
such as the mzML format that is still under development
[8], would be considered.
Nevertheless, after having identified possible solutions for
data formats and vocabulary, the most difficult questions
for the community remain unanswered: what is Minimal
Information? How do we fix the standards for unambigu-
ous material description? There is a lot to learn from past
experience.
Minimal Information
It has been proposed to create three levels of information:
what must be annotated, what should be accessible, and
what is optional to insert [13]. Minimal information
means that a set of metadata, sufficient to evaluate the
data reliability, must be annotated, selecting unambigu-
ous definitions. In other words, MI will request only com-
pulsory data that are the minimal requirements for quality
evaluation. Nevertheless, the same format could also host
advanced information (for instance, the kind of informa-
tion that now is boxed into manuscript supplementary
data), and annotations mostly intended for internal use
(lab archive of material and specific details for lab praxis
optimization). However, these supplementary data will
also be annotated using a standardized structure, with the
aim of simplifying further retrieval and analyses avoiding
loss of technical intelligence. The main advantage would
be having data and metadata archived in an easily accessi-
ble form [15].
An example of Minimal Information on material and
experimental condition description could correspond to
the requests summarized in Table 1. A proposal of Mini-
mal Information for functional/structural quality evalua-
tion of specific protein manipulation is shown in Table 2.
Protocols for standardized performances and general
guidelines of good lab praxis would be also considered for
discussion, with the idea of finding a consensus aimed at
more uniform experimental conditions (Table 3).Microbial Cell Factories 2008, 7:20 http://www.microbialcellfactories.com/content/7/1/20
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Towards clear and consistent standards
It is difficult to set exhaustive MI checklists and both
engagement and acceptance from the scientific commu-
nity are critical for the successful adoption of standards
that will allow: a) evaluation of experimental consistency,
and b) straightforward data exchange to get the most out
of produced results [1,13,15]. Consequently, MIPFE plat-
form, as most of the already existing similar initiatives,
should be thought as a flexible tool. A preliminary draft
expressing clear purposes and contents (for instance, a
document extending the annotations reported in Tables 1
to 3) would be made accessible, ideally on an electronic
discussion format, and public criticism and feed-back will
be reviewed and eventually integrated. It has been under-
lined that premature adoption of formalized standards
will result in the successive coexistence of original and
more mature versions [13]. The criticism of producing
annotations that are difficult to compare has been already
expressed for MIAME [13]. Such a confusing situation
would compromise the aim of the initiative since it would
generate metadata in different and contrasting formats,
preventing easy data sharing. Therefore, fixed, clear, and
unambiguous standards should be defined and imple-
mented only after comprehensive vetting by the commu-
nity to avoid nebulous reporting consistency allowed by
subjective interpretations of the requested detail level.
Platform simplicity would be accomplished for avoiding
that annotations could represent a burden for the scientist
work.
Lobbing for MIPFE
Accurate (new) analyses may represent a practical obstacle
for some groups, although data reliability would have pri-
ority over technical limitations of single individuals. It
could be objected that microarray and proteomic commu-
Table 1: Material information sheet. The MI concerning the material preparation and characterization is reported
Construct information Accession number; partial sequence?; mutations?; fusions to tags?; rec. Abs: format (Fab, scFv, VHH)
Vector information Vector type and map; cloning sites; resistance; linkers; protease cleavage sites
Hybridoma clone Identification; tests in ELISA, IP, WB, IHC
Chromatographic steps IMAC (column1, buffer 1); Desalting (column 2, buffer 2); .....
Tag cleavage Buffer; cleavage conditions
Protein storage conditions Buffer; temperature; aliquots;
Re-folding Buffer; strategy, glycosylation
Functionality Enzymatic assay; IP; ELISA; IHC; SPR; ITC; Oxidation status (SH/S-S), Appearance, Stability
Purification parameters Yields; Specific activity; KD; Aggregation index; multimerisation, specific activity
Purity host cells proteins, nucleic acids, lipids, carbohydrates, process added chemicals
Table 2: Experimental information check list. MI for each experiment is in bold, optional information is in italics. 
Experiment type Analyses to perform for
evaluating proteins before
  starting the experiments
Protocol references (from a list
of accepted standard protocols
for each experiment type that
   guarantee output congruency)
Equipments
(define minimal requisites of
the devices in terms of
quality, maintenance,
    controls)
Protein pull-down SDS PAGE; AI; SEC; DLS; CD far 
UV; CD near UV; FT-IR; NMR;
SDS: protocol 1 (or protocol 2,..) AI 
protocol 1
SDS: Hoefer minigel....
AI: Spectrofluorimeter Jasco .....
SEC: column xy and FPLC model z.....
Monoclonal Ab purification SDS PAGE; AI; SEC; DLS; CD far 
UV; CD near UV;
Protein purification SDS PAGE; AI; SEC;DLS; CD far 
UV; CD near UV; FT-IR; NMR;
SPR
ITC
ELISA
Enzymatic assay
Protein refolding
Immunoprecipitation
Immunofluorescence
Immunohistochemistry
Proximity ligation
The corresponding pictures (SDS-gels, chromatographic profiles, fluorimeter spectra,.....) would be embedded in the metadata form.
Abbreviations: Aggregation Index (AI) (16), Size Exclusion Chromatography (SEC), Dynamic Light Scattering (DLS), Circular Dichroism (CD), 
Fourier-Transform InfraRed (FT-IR), Nuclear Magnetic Resonance (NMR).Microbial Cell Factories 2008, 7:20 http://www.microbialcellfactories.com/content/7/1/20
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nities already decided that a further effort from scientists
was necessary for improving the value of generated data.
Centralized facilities, specialized in protein and mono-
clonal antibody production, have been implemented in
most of the larger research institutes for providing internal
services. MIPFE could offer a great opportunity for their
growth in terms of reliability and evaluation of results.
Dealing with a large number of technically demanding
but repetitive activities, facilities can afford the commit-
ment to develop standardized quality control analyses
with increasing levels of sophistication that could be dif-
ficult to achieve in non-specialized labs. Moreover, facili-
ties could directly use MIPFE standard forms to annotate
their work output. These forms will have the double
advantage of certifying the activity towards customers and
being already MI metadata annotated in a form directly
usable by the community at large (editors, industry, fund-
ing agencies, researchers).
Journals should be contacted to discuss the implementa-
tion of electronic accessible forms and asked to request
standard compliance as a condition for publication. Nota-
bly, this already happens for compulsory submission of
DNA sequences to data repositories [1] and in the case of
proteomics [7,8]. The main limitation is the lack of cen-
tralized repository data-bank, a general issue for any MI
initiative, and journal websites would have to supply one
for metadata storage. Fortunately, funding agencies
become more and more sensitive to the MI initiatives
[1,3] in the light of recognition that such platforms are
crucial for efficient data dissemination and they will prob-
ably provide the necessary support in the next future. Fur-
thermore, publicly supported initiatives, like Addgene
(see Availability and requirements section for URL), may
help in simplifying storage and availability of material
used in the experiments.
The integration of MIPFE in one of the already pre-existing
platforms would be investigated in the effort to avoid
overlap among platforms.
Conclusion
When MIAPE [3] was introduced, the authors underlined
the necessity to contextualize data with "metadata". For
instance, the statement that "the sequence corresponding
to amino-acids 197 to 259 of NPM interacts with the N-
terminus of Arf as shown by pull-down experiments"
should be supported by a biochemical validation of the
correct folding of both fragments, since access to informa-
tion concerning how data were generated is crucial to
judge their reliability. In practice, such metadata are often
completely missing, with the paradox of having accuracy
in down-stream experiments (annotated metadata for
protein-protein interaction experiments), but no informa-
tion about functionality of the molecules involved in the
experiments that yielded the initial observation. It is
somehow astonishing that every kind of control is
requested for evaluating an experiment, except for the
quality of the proteins involved. Therefore, manuscripts
should be accompanied by a Minimal Information,
organized in a standard format, both for evaluating pro-
tein structure and functionality, and for easy retrieval of
data from different experiments/publications to use for
systematic bioanalysis. In conclusion, a platform would
be developed that is concerned not only with optimiza-
tion of data sharing, but also with how material is control-
led and data are generated. The mandatory control
experiments and standardized annotation of data con-
cerning protein functionality may be considered limiting
the freedom of the scientific activity. However, MI anno-
tation does not interfere with the scientific work, but only
provides information to judge the reliability of produced
results and the possibility of unambiguous data evalua-
tion remains the backbone of scientific practice. It can be
expected that improved data transparency will also
increase the public acceptance for research funding.
In contrast to well defined scientific communities as, for
instance, those operating in proteomics or microarrays,
there is no already established organization exclusively
devoted to protein production that could promote a plat-
form like MIPFE. However, the subject will be discussed in
the forthcoming Recombinant Protein Production con-
gress (see Availability and requirements section for URL)
organized by the Microbial Physiology section of the
European Federation of Biotechnology and I expect to
contribute to the effort with the observations reported in
this commentary. The hope is that all together this infor-
mation and discussions might catalyze the interest of sev-
eral actors to establish a core community for the
development of the MIPFE platform.
Table 3: General guidelines for good lab praxis.
Clone only in expression vectors that allow cleavage of the tag after purification. Advantage: any side effect due to the tag can be evaluated
Cleave the tag before using the target protein in interaction experiments. Advantage: unspecific interactions can be limited
Prepare mono-use aliquots of the purified protein. Advantage: reproducibility of the experiment is improved
Perform an experiment to evaluate protein stability after incubation on ice or at room temperature at different times; stability for freeze/thaw, if 
applicable. Advantage: experiment design is optimizedPublish with BioMed Central    and   every 
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Availability and requirements
MIBBI: http://mibbi.sourceforge.net
Human Proteinpedia: http://www.humanproteinpe
dia.org
OBI: http://obi.sourceforge.net
FuGE: http://fuge.sourceforge.net
Addgene: http://www.addgene.org
Recombinant Protein Production congress: http://
www.ing.univpm.it/rpp2008/welcome.htm
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